hat free antibody light chains are elevated in many inflammatory diseases suggest that they may be novel therapeutic targets. F1000Pdme Report by Judith A. Brebner and Robert A. Stockley. Coming Soonl F1000Trials will identify all the clinical trials and systematic reviews published in the key general medic